Velicept's overactive bladder therapy meets in Phase IIb

Velicept said solabegron met the primary endpoint in the Phase IIb VEL-2002 trial to treat overactive bladder. The company plans to start

Read the full 222 word article

How to gain access

Continue reading with a
two-week free trial.